{
  "symbol": "DNLI",
  "company_name": "Denali Therapeutics Inc",
  "ir_website": "https://denalitherapeutics.gcs-web.com/node/8826/html",
  "structured_data": [
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "0001193125-22-077264.rtf",
          "url": "https://denalitherapeutics.gcs-web.com/static-files/50eaefc5-fbc8-45c2-ad32-1f9434567a53",
          "content": null
        },
        {
          "title": "0001193125-22-077264.pdf",
          "url": "https://denalitherapeutics.gcs-web.com/static-files/66e7abdd-eaa5-4ce8-a3f7-394a5c89a5c3",
          "content": "\n"
        },
        {
          "title": "0001193125-22-077264.xls",
          "url": "https://denalitherapeutics.gcs-web.com/static-files/da23a829-d2f8-4091-bed4-a55c952147ae",
          "content": null
        },
        {
          "title": "0001193125-22-077264-ex-101-sch---xbrl-taxonomy-extension-schema.xsd",
          "url": "https://denalitherapeutics.gcs-web.com/sec-filings/sec-filing/8-k/0001193125-22-077264",
          "content": "[Skip to content](#lfg-main-content)\n\n[ Skip to main content ](#main-content)\n\n×\n\n#  SEC Filing Details \n\n## Document Details\n\nForm\n\n[ 8-K ](/node/8826/html)\n\nFiling Date\n\nMar 15, 2022\n\nDocument Date\n\nMar 13, 2022\n\nForm Description\n\nReport of unscheduled material events or corporate event\n\nFiling Group\n\nCurrent Reports (8-K)\n\nCompany\n\nDenali Therapeutics\n\nIssuer\n\nDenali Therapeutics Inc.\n\n## Filing Formats\n\n[iXBRL](/node/8826/ixbrl-viewer)\n\n[View HTML](/node/8826/html)\n\n[Download PDF](/static-files/66e7abdd-eaa5-4ce8-a3f7-394a5c89a5c3 \"0001193125-22-077264.pdf\")\n\n[Download DOC](/static-files/50eaefc5-fbc8-45c2-ad32-1f9434567a53 \"0001193125-22-077264.rtf\")\n\n[Download XLS](/static-files/da23a829-d2f8-4091-bed4-a55c952147ae \"0001193125-22-077264.xls\")\n\n## XBRL\n\n[XBRL Viewer](/node/8826/xbrl-viewer)\n\n[EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/static-files/e7402984-993e-40cf-9fb8-9526b13ca56c \"0001193125-22-077264-ex-101-sch---xbrl-taxonomy-extension-schema.xsd\")\n\n[EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE](/static-files/8351cbfa-d925-42e3-903f-066ad0e92ecf \"0001193125-22-077264-ex-101-lab---xbrl-taxonomy-extension-label-linkbase.xml\")\n\n[EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE](/static-files/58829007-5763-4d7a-90f9-1f302914d684 \"0001193125-22-077264-ex-101-pre---xbrl-taxonomy-extension-presentation-linkbase.xml\")\n\n[XML - XBRL INSTANCE DOCUMENT](/static-files/74d8c3be-4643-4db1-93a2-38d1d54e810a \"0001193125-22-077264-xml---xbrl-instance-document.xml\")\n\n## Sign up for email alerts\n\nStay in the loop with updates on the latest Denali news delivered right to your inbox\n\nSubmit\n\n  * [Investor & Media Relations](/)\n\n\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\nACCEPT NO THANKS\n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Release dated March 15, 2022.",
          "url": "https://denalitherapeutics.gcs-web.com#d310285dex991.htm",
          "content": "[Skip to content](#lfg-main-content)\n\n[ Skip to main content ](#main-content)\n\n×\n\n#  Investor & Media Relations \n\nWe discover and develop medicines to defeat neurodegeneration.\n\nThe science is breaking open and the time is right for an ambitious and rigorous effort to address Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. We are applying deep scientific and drug development expertise to discover effective molecular therapeutics and have engineered a proprietary technology to deliver biologic therapeutics to the brain.\n\nWith a team of experienced and passionately dedicated scientists and drug developers, we believe we can succeed in meaningfully improving the lives of patients and their families.\n\n![Denali Nasdaq](/sites/g/files/knoqqb84466/themes/site/client_site/overwrite/sites/default/files/2020-10/Denali_Nasdaq.jpg)\n\n## Press Releases\n\n![](sites/g/files/knoqqb84466/themes/site/client_site/overwrite/sites/default/files/2022-06/loading_0.gif)\n\nDenali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights \n\nNov 06, 2024\n\n[Read More](/news-releases/news-release-details/denali-therapeutics-reports-third-quarter-2024-financial-results)\n\nDenali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) \n\nSep 03, 2024\n\n[Read More](/news-releases/news-release-details/denali-therapeutics-announces-successful-meeting-fda-and-plans)\n\nDenali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration \n\nAug 14, 2024\n\n[Read More](/news-releases/news-release-details/denali-therapeutics-announces-publication-science-translational)\n\n[VIEW ALL](/news-releases)\n\n## Events\n\nDec 3, 2024 12:30 PM EST\n\n[7th Annual Evercore ISI HealthCONx Conference](/events/event-details/7th-annual-evercore-isi-healthconx-conference)\n\n[Webcast](https://wsw.com/webcast/evercore44/dnli/2351349)\n\n[VIEW ALL](/events)\n\n## Corporate Presentation\n\n[DNLI CORPORATE PRESENTATION - NOVEMBER 2024](/static-files/6932f0a6-8907-4919-8bd4-ee81d607a19a)\n\nNovember 18, 2024\n\n[Download PDF](/static-files/6932f0a6-8907-4919-8bd4-ee81d607a19a)\n\n  * Change\n  * Volume\n  * Market Cap\n  * Today's Open\n  * Previous Close\n\n\n  * Exchange\n\nNASDAQ\n\n  * Today's High\n  * Today's Low\n  * 52 Week High\n  * 52 Week Low\n\n\n\nMinimum 15 minutes delayed. Source: LSEG\n\n### Analyst Coverage\n\nView detailed list of firms and analysts.\n\n[View Coverage ](/analyst-coverage)\n\n### SEC Filing\n\nView, download, and share all SEC Filing documents.\n\n[View Documents ](/sec-filings)\n\n### Corporate Governance\n\nView, download, and share Corporate Governance documents.\n\n[View Documents ](/governance)\n\n##  FAQs \n\n[WHERE IS DENALI INCORPORATED?](#0)\n\nDenali Therapeutics Inc. was incorporated in Delaware in October 2013 \n\n[WHERE IS DENALI’S CORPORATE HEADQUARTERS?](#1)\n\nDenali is headquartered in South San Francisco, CA. \n\n[WHEN IS DENALI’S FISCAL YEAR-END?](#2)\n\nDenali's fiscal year ends December 31st \n\n[WHO IS DENALI’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM?](#3)\n\nErnst & Young LLP is Denali's independent registered public accounting firm\n\n[ON WHICH EXCHANGE IS DENALI LISTED, WHAT IS THE TICKER SYMBOL, AND WHEN DID DENALI GO PUBLIC?](#4)\n\nDenali is traded on the NASDAQ Global Select Stock Market under the ticker symbol \"DNLI\"\n\nDenali initial public offering occurred on December 8, 2017\n\n[WHAT IS THE CUSIP NUMBER FOR DENALI’S COMMON STOCK?](#5)\n\n24823R 105\n\n[WHO IS DENALI’S TRANSFER AGENT AND HOW DO I CONTACT THEM?](#6)\n\n**Broadridge Financial Solutions**\n\n5 Dakota Drive, Suite 300, Lake Success, NY 11042 +1 800 353 0103\n\n<https://www.broadridge.com/contact>\n\n[HOW CAN I GET A COPY OF YOUR ANNUAL REPORT OR OTHER PERIODIC REPORTS?](#7)\n\nElectronic copies of our Annual Report and other periodic reports are available on this website. If you would like to request paper copies of the Annual Report or other periodic reports, send your request in writing to:\n\nDenali Therapeutics Inc.\n\nAttn: Corporate Secretary\n\n151 Oyster Point Blvd\n\nSouth San Francisco, CA 94080\n\n[HOW DO I CONTACT DENALI WITH ADDITIONAL QUESTIONS OR INQUIRIES?](#8)\n\nPlease use the [Contact form](https://www.denalitherapeutics.com/contact) for additional questions or inquiries.\n\n## Sign up for email alerts\n\nStay in the loop with updates on the latest Denali news delivered right to your inbox\n\nSubmit\n\n  * [Leadership](https://www.denalitherapeutics.com/leadership)\n\n\n\nWe use cookies on this site to enhance your user experience. By clicking the Accept button, you agree to us doing so.\n\nACCEPT NO THANKS\n"
        }
      ]
    }
  ]
}